Aquestive Therapeutics (AQST) Non-Current Deffered Revenue (2019 - 2026)

Aquestive Therapeutics' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $19.1 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 3.17% year-over-year to $19.1 million in Q1 2026; TTM through Mar 2026 was $19.1 million, a 3.17% decrease from a year earlier, with the FY2025 full-year figure at $19.4 million, down 3.07% from the prior year.
• Non-Current Deffered Revenue eased to $19.1 million in Q1 2026 per AQST's latest filing, from $19.4 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $33.1 million in Q2 2023 and bottomed at $13.5 million in Q2 2022.
• The 5-year median for Non-Current Deffered Revenue is $20.0 million (2024), against an average of $23.5 million.
• Across the five-year window, Non-Current Deffered Revenue soared 341.13% in 2022 and sank 38.22% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $31.4 million in 2022, then grew by 2.95% to $32.3 million in 2023, then tumbled by 38.15% to $20.0 million in 2024, then slipped by 3.07% to $19.4 million in 2025, then fell by 1.4% to $19.1 million in 2026.
• Per Business Quant, the three latest AQST Non-Current Deffered Revenue figures stand at $19.1 million (Q1 2026), $19.4 million (Q4 2025), and $19.7 million (Q3 2025).